Shoulder Innovations, Inc. (SI)
| Market Cap | 265.11M |
| Revenue (ttm) | 47.32M +49.6% |
| Net Income | -40.36M |
| EPS | -4.65 |
| Shares Out | 20.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,182 |
| Open | 12.28 |
| Previous Close | 12.28 |
| Day's Range | 12.06 - 12.90 |
| 52-Week Range | 10.92 - 17.94 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.80 (+62.63%) |
| Earnings Date | May 13, 2026 |
About SI
Shoulder Innovations, Inc. designs, develops, manufactures, and distributes implant systems for shoulder arthroplasty in the United States. It designs InSet Glenoid technology that aims to reduce mechanical stress at the bone implant interface, improve fixation mechanics, enhance stability, and reduce micromotion. The company was incorporated in 2009 and is headquartered in Grand Rapids, Michigan.
Financial Performance
In 2025, Shoulder Innovations's revenue was $47.32 million, an increase of 49.63% compared to the previous year's $31.62 million. Losses were -$40.36 million, 158.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SI stock is "Strong Buy." The 12-month stock price target is $20.8, which is an increase of 62.63% from the latest price.
News
Shoulder Innovations Earnings Call Transcript: Q4 2025
Delivered 65% Q4 and 50% full-year revenue growth in 2025, driven by rapid surgeon adoption, new product launches, and strong ASC penetration. 2026 guidance targets 31–37% revenue growth, with stable margins and continued investment in innovation and commercial expansion.
Shoulder Innovations Transcript: 2026 CG Musculoskeletal Conference
Shoulder arthroplasty is experiencing rapid growth, driven by innovative implants, AI-enabled planning, and a shift to outpatient procedures. New product launches and a robotics-as-a-service model are set to further differentiate offerings and support expansion beyond the U.S.
Shoulder Innovations Transcript: Piper Sandler 37th Annual Healthcare Conference
Leadership leverages decades of experience to drive innovation in shoulder arthroplasty, with strong growth among high-volume surgeons and a focus on portable, ASC-friendly robotics. Financial outlook remains positive, with robust margins and plans to expand indications in 2026.
Shoulder Innovations Transcript: Jefferies London Healthcare Conference 2025
Operating in a $2.8B global market, the company leverages innovative implant and AI planning technologies to address key clinical challenges and ASC logistics. Recent regulatory wins and new product launches are set to expand market reach and improve margins.
Shoulder Innovations Earnings Call Transcript: Q3 2025
Q3 revenue rose 58% year-over-year to $11.8M, with gross margin at 76.2% and strong cash reserves of $137M. Full-year guidance was raised to $45–$46M, reflecting robust adoption, new product launches, and continued expansion in high-volume surgeon users.
Shoulder Innovations Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A leading player in the shoulder arthroplasty market reported 33% Q2 revenue growth, driven by innovative two-tray instrumentation, strong adoption, and a scalable commercial model. Recent IPO proceeds will fund commercial expansion and technology development, with continued focus on ASCs and enabling tech.
Shoulder surgery-focused medtech Shoulder Innovations files for a $100 million IPO
Shoulder Innovations, which offers advanced implant systems for shoulder arthroplasty, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Shoulder Innovations IPO Registration Document (S-1)
Shoulder Innovations has filed to go public with an IPO on the New York Stock Exchange (NYSE).